

# Lydia Warburton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2115723/publications.pdf>

Version: 2024-02-01

13  
papers

351  
citations

1039406

9  
h-index

1125271

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

607  
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. <i>Cancer Letters</i> , 2017, 404, 62-69.	3.2	98
2	Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. <i>BMC Cancer</i> , 2018, 18, 726.	1.1	77
3	Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor <sc>DNA</sc> in metastatic melanoma. <i>Molecular Oncology</i> , 2019, 13, 171-184.	2.1	44
4	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 5926-5933.	3.2	41
5	Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 26-30.	0.7	18
6	Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. <i>British Journal of Cancer</i> , 2022, 126, 401-408.	2.9	18
7	The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond BRAF Mutant Detection. <i>Cancers</i> , 2020, 12, 3793.	1.7	12
8	Intra- and intertumoral heterogeneity of liver metastases in a patient with uveal melanoma revealed by single-cell RNA sequencing. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a006111.	0.5	11
9	Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression. <i>Cancers</i> , 2020, 12, 3486.	1.7	10
10	Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report. <i>BMC Cancer</i> , 2019, 19, 1109.	1.1	9
11	First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 417-431.	2.0	6
12	Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100405.	0.7	6
13	Ipilimumab- and nivolumab-associated enterocolitis with florid necrotising granulomatous inflammation: a novel manifestation of “immunomodulatory” enterocolitis. <i>Pathology</i> , 2018, 50, 466-469.	0.3	1